Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
(Hinzugefügt: 06.03.2023 um 15:18 Uhr)
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions
(Hinzugefügt: 29.03.2022 um 10:28 Uhr)
Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2
(Hinzugefügt: 27.03.2022 um 07:54 Uhr)
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response
(Hinzugefügt: 13.12.2021 um 11:10 Uhr)
Immunizations with diverse sarbecovirus receptor binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability
(Hinzugefügt: 01.11.2021 um 09:57 Uhr)
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
(Hinzugefügt: 17.04.2021 um 09:47 Uhr)
Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology
(Hinzugefügt: 23.03.2021 um 15:48 Uhr)
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses
(Hinzugefügt: 20.01.2021 um 08:11 Uhr)
Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses
(Hinzugefügt: 10.12.2020 um 09:54 Uhr)